key: cord-0952962-emghfozw
authors: Zhang, Rui‐kun; Xiao, Qi; Zhu, Sheng‐lang; Lin, Hai‐yan; Tang, Ming
title: Using different machine learning models to classify patients into mild and severe cases of COVID‐19 based on multivariate blood testing
date: 2021-09-25
journal: J Med Virol
DOI: 10.1002/jmv.27352
sha: 33ff5b02e9122e32ad1b43aca2968924e3b138e1
doc_id: 952962
cord_uid: emghfozw

COVID‐19 is a serious respiratory disease. The ever‐increasing number of cases is causing heavier loads on the health service system. Using 38 blood test indicators on the first day of admission for the 422 patients diagnosed with COVID‐19 (from January 2020 to June 2021) to construct different machine learning (ML) models to classify patients into either mild or severe cases of COVID‐19. All models show good performance in the classification between COVID‐19 patients into mild and severe disease. The area under the curve (AUC) of the random forest model is 0.89, the AUC of the naive Bayes model is 0.90, the AUC of the support vector machine model is 0.86, and the AUC of the KNN model is 0.78, the AUC of the Logistic regression model is 0.84, and the AUC of the artificial neural network model is 0.87, among which the naive Bayes model has the best performance. Different ML models can classify patients into mild and severe cases based on 38 blood test indicators taken on the first day of admission for patients diagnosed with COVID‐19.

predicting the occurrence of COVID-19 critical illness is an important direction for the treatment of COVID-19. Machine learning (ML) algorithms have been widely used in the diagnosis, prediction, and other fields of COVID-19 due to their powerful complex data processing capabilities. 9 ,10 A meta-analysis showed that different ML models (RIDGE regression, random forest, and LASSO regression) can effectively differentiate COVID-19 patients and type A influenza patients, 11 12 In previous studies, the clinical variable indicators used to identify patients with mild and severe cases were determined. 13 Due to blood tests being efficient, simple, low-cost, and fast, they have become an alternative plan for the early identification of COVID-19 patients. [14] [15] [16] Currently, there are studies that apply ML models to blood test indicators to diagnose COVID-19 patients. 17 However, there has been no report on differentiating COVID-19 mild cases and severe cases solely based on the blood test indicators. At the same time, the condition of severe and critically ill patients with COVID-19 develops rapidly, with multiple organ failures including respiratory failure. It is difficult to treat with a high fatality rate, and generally comes with poor prognosis. This has had a great impact on medical staff and the healthcare system. How to early identify and actively intervene in severe and critically ill patients is one of the keys to reduce the mortality rate of COVID-19 patients and improve their prognoses. Therefore, this study examines 422 COVID-19 patients diagnosed at Shenzhen Third People's Hospital based on the blood indicators collected on the first day of their diagnosis and admission, different ML models are then built around these data. Internal verifications are then conducted to classify COVID-19 patients with mild and severe cases of COVID-19 to compare the accuracy of each model's prediction.

This study is a retrospective analysis. The subjects of the study are patients who were diagnosed with COVID-19, who were admitted, and hospitalized in Shenzhen Third People's Hospital from January 2020 to June 2021. All patients were examined due to either having close contact with patients or having fevers and other respiratory symptoms that are related to COVID-19. The standard of diagnosis is for real-time fluorescent reverse transcription-polymerase chain reaction (RT-PCR) to detect the positive nucleic acid of COVID-19, that is, the PCR method is used to detect the nucleic acid fragment of the coronavirus. A positive test is defined as the viral load being higher than the lower threshold of the COVID-19 nucleic acid detection reagent. It is confirmed that the patient is diagnosed with COVID-19 after a second review at the Shenzhen Centers for Disease Control and Prevention still turns out to be positive. All patient information is recorded in the electronic medical record system of Shenzhen Third People's Hospital. To protect patients' privacy, all patients have their personal identification information removed, and each patient only retains a unique randomly generated digital identity tag. This study extracted information on all COVID-19 cases recorded in the electronic medical journal system as of June 2021. The exclusion criterion are: less than 18 years old of age, admission time for less than 2 days, patients that are missing more than 75% of their data.

We collected blood test indicators of patients on the first day of admission. All data were extracted from electronic medical records. A total of 38 indicator variables (lactic acid, potassium ion, sodium ion, white blood cell, neutrophil ratio, neutrophil count, Lymphocyte ratio, lymphocyte count, hematocrit, hemoglobin, platelets, alanine aminotransferase, aspartate aminotransferase, total bilirubin, direct bilirubin, albumin, globulin, lactate dehydrogenase, urea, creatinine, β−2M, cystostatin C, creatine kinase, creatine kinase isoenzyme, B-type natriuretic peptide, troponin I, killer T cells, helper T cells, suppressor T cells, erythrocyte sedimentation rate, C Reactive protein, procalcitonin, interleukin 6, prothrombin time, activated partial thromboplastin time, fibrin, D dimer, and PaO 2 / FiO 2 ) were collected. This study was approved by the Ethics Committee of Shenzhen Third People Hospital. 

This study chose seven ML models: random forest, naïve Bayes, SVM, KNN, logic regression, and artificial neural network. The data were randomly separated into two parts. We randomly divided the data into 80% training data set and 20% test data set. In the training data set, 38 blood indicator variables were used as input to construct the corresponding model. The model is used to classify patients with mild and severe COVID-19. The models are then put through a fivefold cross-validation process and grid searches automatically optimize to determine the best hyperparameters. The hyperparameters that need to be adjusted include but is not limited to the max depth and n_estimators for the random forest model and learning rate for the artificial neural network model. Next, the model trained in the training set is used in the test data set for internal verification to evaluate the performance of the model in classifying patients with mild and severe COVID-19. Training and testing sets' baseline demographics are shown in Table S1 . All ML is done through Python using numpy (v1.19), scikit-learn (v0.24), and tensorflow (v2.5). The process is shown in Figure 1 .

We evaluated the accuracy of the model by drawing the receiver operating characteristic (ROC) curve and the precision-recall (PR) curve in the test data set, and used the following equations to calculate the sensitivity and specificity to evaluate the performance of the model:

Finally, the area under the ROC curve (AUC) of different models is compared. The 95% confidence interval (CI) of the AUC is then obtained by repeatedly resampling with replacement 1000 times in the test data set using bootstrapping procedure. Research reports have shown that Cystatin C can be used as a potential biomarker to predict the adverse outcomes of SARS-CoV-2

infection. 24 It is also an independent risk factor predicting the death of COVID-19's critically ill patients. 22 In addition, it is generally believed that SARS-CoV-2 can induce immune disorders and excessive inflammation, 25, 26 which is mainly manifested in the depletion of peripheral blood lymphocytes and cytokine cascades. SARS-CoV-2

can cause a specific T cell response and activated Th1 (T helper cells) pass NF-kB. 27 The signaling pathway produces a pro-inflammatory response and causes a downstream cytokine storm leading to diffuse lung tissue damage, 28 which can even lead to death of the patient. 29 Lymphopenia is the most consistent laboratory abnormality in patients infected with COVID-19 and it can be observed in up to 72%-85% of severe cases, 28 There are also research reports showing that lymphocyte subsets can be used for early screening of severe COVID-19. 32 In addition, SARS-CoV-2 infection can also trigger a cytokine storm through the JAK/ STAT pathway and produce various inflammatory markers through hosts such as macrophages, monocytes, and lymphocytes, 33 among which IL-6 is an important inflammatory biomarker, mainly produced by macrophages. 34 The overproduction of IL-6 can trigger the biological effects of organ damage, so it is the main pro-inflammatory mediator that induces the acute phase response, 35 

In this study, different ML models were constructed based on 38 blood indicators variables of patients diagnosed with COVID-19 on the first day of admission, which can more accurately classify patients into mild and severe cases of COVID-19.

Yi-jin Yang at Shenzhen University provided English editing assistance.

All patients who participated also consented to the publication of this manuscript. This study has been approved by the Ethics Committee 

Due to institutional restrictions on data sharing and privacy issues, the data set generated and/or analyzed during the current research period has not been publicly available. However, the data and code can be obtained from the corresponding author upon reasonable requests.

Rui-kun Zhang http://orcid.org/0000-0001-6455-4617

Effectiveness of COVID-19 diagnosis and management tools: a review

COVID-19 diagnosis and management: a comprehensive review

The SARS-CoV-2 outbreak: what we know

Clinical characteristics of Coronavirus disease 2019 in China

Critical care utilization for the COVID-19 outbreak in Lombardy, Italy: early experience and forecast during an emergency response

Characteristics of and important lessons from the Coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention

Common cardiovascular risk factors and in-hospital mortality in 3,894 patients with COVID-19: survival analysis and machine learning-based findings from the multicentre Italian CORIST Study

Predictors of mortality in hospitalized COVID-19 patients: a systematic review and meta-analysis

Artificial intelligence-enabled rapid diagnosis of patients with COVID-19

Prediction models for diagnosis and prognosis of covid-19: systematic review and critical appraisal

Using machine learning of clinical data to diagnose COVID-19: a systematic review and meta-analysis

Machine learning based early warning system enables accurate mortality risk prediction for COVID-19

Clinical diagnosis of severe COVID-19: a derivation and validation of a prediction rule

Hematologic parameters in patients with COVID-19 infection

Routine blood tests as a potential diagnostic tool for COVID-19

Complete blood count might help to identify subjects with high probability of testing positive to SARS-CoV-2

Development, evaluation, and validation of machine learning models for COVID-19 detection based on routine blood tests

Missing-data methods for generalized linear models: a comparative review

Diagnosis and treatment protocol for novel coronavirus pneumonia (trial version 7). Zhonghua yixue zazhi

Development and validation of a clinical risk score to predict the occurrence of critical illness in hospitalized patients With COVID-19

Clinical characteristics of 138 hospitalized patients with 2019 novel Coronavirus-infected Pneumonia in Wuhan, China

Predictive value of serum cystatin C for risk of mortality in severe and critically ill patients with COVID-19

Involvement of cystatin C in immunity and apoptosis

Serum Cystatin C and Coronavirus disease 2019: a potential inflammatory biomarker in predicting critical illness and mortality for adult patients

The many faces of the anti-COVID immune response

Immune environment modulation in pneumonia patients caused by coronavirus: SARS-CoV, MERS-CoV and SARS-CoV-2

The COVID-19 pandemic: a target for surfactant therapy?

Severe COVID-19: what have we learned with the immunopathogenesis?

Early expansion of myeloidderived suppressor cells inhibits SARS-CoV-2 specific T-cell response and may predict fatal COVID-19 outcome

Reduction and functional exhaustion of T cells in patients with Coronavirus disease 2019 (COVID-19)

The many faces of the anti-COVID immune response

Dysregulation of immune response in patients with Coronavirus

JAK-STAT pathway inhibition and their implications in COVID-19 therapy

COVID-19 and the immune system

Defective inflammatory response in interleukin 6-deficient mice

The four horsemen of a viral apocalypse: the pathogenesis of SARS-CoV-2 infection (COVID-19)

Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors

Clinical presentation and management of COVID-19

Immune responses in COVID-19 and potential vaccines: lessons learned from SARS and MERS epidemic

Using different machine learning models to classify patients into mild and severe cases of COVID-19 based on multivariate blood testing